Working... Menu
Trial record 64 of 81 for:    CRVO - Central Retinal Vein Occlusion

Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab (RAVEN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01471691
Recruitment Status : Completed
First Posted : November 16, 2011
Results First Posted : April 29, 2015
Last Update Posted : April 29, 2015
Genentech, Inc.
Information provided by (Responsible Party):
Hanscom, Thomas, M.D.

Brief Summary:
This study examines two doses of Ranibizumab (0.5mg and 1.0mg) for the treatment of macular edema secondary to retinal vein occlusion in patients that have previously failed treatment with other macular edema treatments including bevacizumab.

Condition or disease Intervention/treatment Phase
Branch Retinal Vein Occlusion Central Retinal Vein Occlusion Macular Edema Drug: ranibizumab 0.5mg Drug: ranibizumab 1.0mg Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II, Open-label, Study of Intravitreal RAnibizumab 0.5MG, or High Dose 1.0mg for Retinal Vein Occlusions With rEfractory Macular Edema Previously Receiving iNtravitreal Bevacizumab (RAVEN)
Study Start Date : November 2011
Actual Primary Completion Date : February 2014
Actual Study Completion Date : February 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema

Arm Intervention/treatment
Experimental: intravitreal ranibizumab 0.5mg Drug: ranibizumab 0.5mg
Standard dose
Other Name: Lucentis

Experimental: intravitreal ranibizumab 1.0mg Drug: ranibizumab 1.0mg
High dose
Other Name: Lucentis

Primary Outcome Measures :
  1. Mean Change From Baseline BCVA [ Time Frame: Baseline to month 6 ]
    Vision was measured using a standard ETDRS chart at baseline and each subsequent monthly visit.

Secondary Outcome Measures :
  1. Mean Change From Baseline in Center Point Thickness [ Time Frame: months 1-12 ]
  2. Change in Mean Best Corrected Visual Acuity From Baseline [ Time Frame: months 1-12 ]
  3. Percentage of Patients With CFT Less Than 300um [ Time Frame: Month 6 and 12 ]
  4. Excess Foveal Thickness [ Time Frame: Month 6 and 12 ]
  5. Total Number of Ranibizumab Injections [ Time Frame: month 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Age > 18 years
  • CRVO or BRVO diagnosis
  • For CRVO, clinical evidence of perfused central retinal vein occlusion. A CRVO is defined as an eye that has retinal hemorrhages and a dilated retinal venous system in all 4 quadrants. Other evidence of a CRVO may include telangiectatic capillary bed and collateral vessels at the optic nerve head.
  • Central macular edema present on clinical examination and OCT testing with a central point thickness and/or central 1mm subfield thickness > 300 microns after at least 3 months of bevacizumab or steroid therapy.
  • Visual acuity score greater than or equal to 19 letters (20/400) and less than or equal to 73 letters (20/40) by the ETDRS visual acuity protocol.
  • Patients must demonstrate that they are no longer improving on bevacizumab or intravitreal steroid therapy (i.e. no improvement in acuity in 2 consecutive visits)
  • BRVO patients treated with grid laser must show residual edema three months following latest laser treatment
  • Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography

Exclusion Criteria:

  • Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women not using adequate contraception.
  • Participation in another ocular investigation or trial simultaneously
  • Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g. chronic alcoholism, drug abuse)
  • Significant diabetic retinopathy (greater than moderate NPDR) or macular edema associated with diabetic retinopathy
  • An eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of subretinal fibrosis or geographic atrophy or severe epiretinal membrane)
  • Presence of another ocular condition that may affect the visual acuity or macular edema during the course of the study (e.g. AMD, uveitis, Irvine-Gas)
  • Evidence of neovascularization of the iris or retina (presence of ischemic CRVO/BRVO)
  • Evidence of central atrophy or fibrosis in the study eye
  • Presence of substantial cataract, one that might decrease the vision by 3 or more lines of vision at sometime during the study.
  • History of grid/focal laser or panretinal laser in the study eye in the previous three months
  • History of vitreous surgery in the study eye
  • History of use of intravitreal, peribulbar, or retrobulbar steroids within three months of the study.
  • History of cataract surgery within 6 months of enrollment.
  • History of YAG capsulotomy within 2 months of the surgery.
  • Visual acuity <20/400 in the fellow eye
  • Uncontrolled glaucoma (pressure >30) despite treatment with glaucoma medications.
  • History of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01471691

Layout table for location information
United States, California
South Coast Retina
Huntington Beach, California, United States, 92647
South Coast Retina
Long Beach, California, United States, 90807
Thomas Hanscom AMC
Santa Monica, California, United States, 90404
South Coast Retina
Torrance, California, United States, 90505
Sponsors and Collaborators
Hanscom, Thomas, M.D.
Genentech, Inc.
Layout table for investigator information
Principal Investigator: Thomas O'Hearn, MD Thomas Hanscom AMC

Layout table for additonal information
Responsible Party: Hanscom, Thomas, M.D. Identifier: NCT01471691     History of Changes
Other Study ID Numbers: ML27847
First Posted: November 16, 2011    Key Record Dates
Results First Posted: April 29, 2015
Last Update Posted: April 29, 2015
Last Verified: April 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Retinal Vein Occlusion
Retinal Degeneration
Retinal Diseases
Venous Thrombosis
Macular Edema
Signs and Symptoms
Macular Degeneration
Eye Diseases
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors